Ablacon, Inc, a company supported by Ajax Health, has established a Scientific Advisory Board that will include four leaders in the field of electrophysiology to guide the company in its development of Ablamap, a mapping solution to guide treatment of atrial fibrillation, it was reported on Tuesday.

The four leaders who have joined the Scientific Advisory Board include Hugh Calkins, MD, an Catherine Ellen Poindexter professor of Medicine, Cardiology and director of the Electrophysiology Laboratory and Arrhythmia Service at the Johns Hopkins Hospital, Baltimore, Maryland; John Hummel, MD, a Professor of Cardiovascular Medicine and director of Clinical Electrophysiology Research section at The Ohio State University, Wexner Medical Center, Columbus, Ohio; Vivek Reddy, MD, the Leona M and Harry B Helmsley Charitable Trust Professor of Medicine in Cardiac Electrophysiology and director of Cardiac Arrhythmia Service, at Mount Sinai Hospital in New York and Atul Verma, MD, the head of the Heart Rhythm Program at Southlake Regional Health Center and Associate Professor at the University of Toronto, Ontario, Canada.

Duke Rohlen, Ablacon's CEO, said, 'We are excited to bring together this distinguished group of experts in electrophysiology at this pivotal time in Ablacon's development. Our team has made enormous progress in product development, scientific validation and clinical demonstration. As we look to the future, we are thrilled to be able to leverage the expertise of this group to bring this innovation to market to enhance patient care in AF.'